Adhera to Develop MLR-1019 for Easing Parkinson’s Symptoms

Adhera to Develop MLR-1019 for Easing Parkinson’s Symptoms

301247

Adhera to Develop MLR-1019 for Easing Parkinson’s Symptoms

Adhera Therapeutics will develop MLR-1019 (armesocarb), a treatment candidate for easing Parkinson’s disease symptoms, following a licensing agreement with Melior Pharmaceuticals II. The therapy is the only one in development that’s designed to treat both Parkinson’s motor and non-motor symptoms simultaneously. “MLR-1019 represents what could be a huge step forward in the field of Parkinson’s disease insomuch that we’re optimistic it can provide patients relief for both movement and non-movement symptoms,” Andrew Kucharchuk, Adhera’s CEO,…

You must be logged in to read/download the full post.